Intra-Cellular Therapies, Inc. (ITCI)

Market Cap	8.85B
Revenue (ttm)	613.73M
Net Income (ttm)	-86.37M
Shares Out	106.02M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	924,121
Open	84.54
Previous Close	84.14
Day's Range	82.77 - 85.03
52-Week Range	62.78 - 93.45
Beta	0.70
Analysts	Strong Buy
Price Target	97.67 (+17.04%)
Earnings Date	Oct 30, 2024

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of vario...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 610
• Stock Exchange: NASDAQ
• Ticker Symbol: ITCI

Financial Performance

In 2023, Intra-Cellular Therapies's revenue was $464.37 million, an increase of 85.51% compared to the previous year's $250.31 million. Losses were -$139.67 million, -45.49% less than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $97.67, which is an increase of 17.04% from the latest price.

Price Target

$97.67

(17.04% upside)

Analyst Consensus: Strong Buy